A Phase I, Randomised, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD0328 in Healthy Young Japanese and Caucasian Male Volunteers After Oral Single and Multiple Ascending Doses.
Phase of Trial: Phase I
Latest Information Update: 15 Jan 2010
At a glance
- Drugs AZD 0328 (Primary)
- Indications Alzheimer's disease; Cognition disorders; Schizophrenia
- Focus Adverse reactions
- Sponsors AstraZeneca
- 27 Oct 2008 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 29 Sep 2008 Planned end date changed from 1 Sep 2008 to 1 Oct 2008 as reported by ClinicalTrials.gov.
- 29 Sep 2008 Planned number of patients changed from 48 to 64 as reported by ClinicalTrials.gov.